Invasive Validation of Arteriograph Estimates of Central Blood Pressure in Patients With Type 2 Diabetes
| Autor: | Niklas B. Rossen, Esben Laugesen, Klavs Würgler Hansen, Christian Daugaard Peters, Eva Ebbehøj, Søren Tang Knudsen, Hans Erik Bøtker, Per Løgstrup Poulsen |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Coronary angiography Validation study medicine.medical_specialty Denmark Blood Pressure Type 2 diabetes Central blood pressure Predictive Value of Tests Diabetes mellitus Internal medicine Catheterization Peripheral Transducers Pressure Internal Medicine medicine Humans In patient Aged business.industry Limits of agreement Reproducibility of Results Blood Pressure Determination Equipment Design medicine.disease Blood pressure Diabetes Mellitus Type 2 Cardiology business Vascular Access Devices |
| Zdroj: | Rossen, N B, Laugesen, E, Peters, C D, Ebbehøj, E, Knudsen, S T, Poulsen, P L, Bøtker, H E & Hansen, K W 2013, ' Invasive Validation of Arteriograph Estimates of Central Blood Pressure in Patients With Type 2 Diabetes ', American Journal of Hypertension . https://doi.org/10.1093/ajh/hpt162 |
| ISSN: | 1941-7225 0895-7061 |
| DOI: | 10.1093/ajh/hpt162 |
| Popis: | BACKGROUND Central blood pressure (BP) has attracted increasing interest because of a potential superiority over brachial BP in predicting cardiovascular morbidity and mortality. Several devices estimating central BP noninvasively are now available. The aim of our study was to determine the validity of the Arteriograph, a brachial cuff-based, oscillometric device, in patients with type 2 diabetes. METHODS We measured central BP invasively and compared it with the Arteriograph-estimated values in 22 type 2 diabetic patients referred to elective coronary angiography. RESULTS The difference (invasively measured BP minus Arteriograph-estimated BP) in central systolic BP (SBP) was 4.4±8.7 mm Hg (P = 0.03). The limits of agreement were ±17.1 mm Hg. CONCLUSIONS Compared with invasively measured central SBP, we found a systematic underestimation by the Arteriograph. However, the limits of agreement were similar to the previous Arteriograph validation study and to the invasive validation studies of other brachial cuff-based, oscillometric devices. A limitation in our study was the large number of patients (n = 14 of 36) in which the Arteriograph was unable to analyze the pressure curves. In a research setting, the Arteriograph seems applicable in patients with type 2 diabetes. CLINICAL TRAIL REGISTRATION ClinicalTrials.gov ID NCT01538290. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|